Ovid Therapeutics (OVID) FCF Margin (2020 - 2026)
Ovid Therapeutics' (OVID) quarterly FCF Margin came in at 2401.09% in Q2 2026, down 232498.0% on a YoY basis from N/an in Q2 2025, and down 65.64% quarter-over-quarter from 1449.58% in Q4 2025.
Powered by 
Analysis
Ovid Therapeutics (OVID) FCF Margin (2020 - 2026) Analysis & Trends
Ovid Therapeutics (OVID) has reported FCF Margin for 7 consecutive years, with 2401.09% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, FCF Margin fell 232498.0% year-over-year to 2401.09%; the trailing twelve-month figure through Jun 2026 stood at 3460.52% (down 285846.0% YoY), and the FY2025 full-year result was 528.6%, up 937352.0% from the prior year.
- FCF Margin declined to 2401.09% in Q2 2026 per OVID's latest filing, from 1449.58% in the prior quarter.
- Across five years, FCF Margin topped out at 76.12% in Q2 2025 and bottomed at 114348.52% in Q3 2022.
- Historically, FCF Margin has averaged 15669.44% across 5 years, with a median of 8948.29% in 2024.
- The widest YoY moves for FCF Margin: up 10512650 bps in 2023, down 1697984 bps in 2023.
- Over 5 years, FCF Margin stood at 20085.72% in 2022, then surged by 58 bps to 8378.87% in 2023, then plunged by 57 bps to 13134.21% in 2024, then jumped by 89 bps to 1449.58% in 2025, then sank by 66 bps to 2401.09% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 2401.09%, 1449.58%, and 9751.52% for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 28.82% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 18.33% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 26.96% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 43.05% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 2.01% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 25.52% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 25.68% |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 29.58% |
| 10 | Ovid Therapeutics | 517.32 Mn | 400.10 Mn | - | -2,401.09% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2,401.09% |
| Dec 31, 2025 | -1,449.58% |
| Sep 30, 2025 | -9,751.52% |
| Jun 30, 2025 | -76.12% |
| Mar 31, 2025 | -7,907.69% |
| Dec 31, 2024 | -13,134.21% |
| Sep 30, 2024 | -8,674.57% |
| Jun 30, 2024 | -8,492.31% |
| Mar 31, 2024 | -11,287.16% |
| Dec 31, 2023 | -8,378.87% |
| Sep 30, 2023 | -9,222.02% |
| Jun 30, 2023 | -15,736.00% |
| Mar 31, 2023 | -18,372.73% |
| Dec 31, 2022 | -20,085.72% |
| Sep 30, 2022 | -114,348.52% |
| Mar 31, 2022 | -1,392.89% |
| Mar 31, 2021 | 77.21% |
| Dec 31, 2020 | -255.26% |
| Sep 30, 2020 | -21.59% |